Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1

International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity
T Skurk, H Hauner

Abstract

Obesity is the central promoter of the metabolic syndrome which also includes disturbed fibrinolysis in addition to hypertension, dyslipidaemia and impaired glucose tolerance/type 2 diabetes mellitus. Plasminogen activator inhibitor-1 (PAI-1) is the most important endogenous inhibitor of tissue plasminogen activator and uro-plasminogen activator, and is a main determinant of fibrinolytic activity. There is now compelling evidence that obesity and, in particular, an abdominal type of body fat distribution are associated with elevated PAI-1 antigen and activity levels. Recent studies established that PAI-1 is expressed in adipose tissue. The greater the fat cell size and the adipose tissue mass, the greater is the contribution of adipose production to circulating PAI-1. Experimental data show that visceral adipose tissue has a higher capacity to produce PAI-1 than subcutaneous adipose tissue. Studies in human adipocytes indicate that PAI-1 synthesis is upregulated by insulin, glucocorticoids, angiotensin II, some fatty acids and, most potently, by cytokines such as tumour necrosis factor-alpha and transforming growth factor-beta, whereas catecholamines reduce PAI-1 production. Interestingly, pharmacological agents such as thiazol...Continue Reading

References

Dec 1, 1992·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·G M PatrassiA Girolami
Nov 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·D J Schneider, B E Sobel
Aug 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·A J van ZonneveldD J Loskutoff
Aug 1, 1993·Metabolism: Clinical and Experimental·B J Potter van LoonA E Meinders
Jan 28, 1998·Arteriosclerosis, Thrombosis, and Vascular Biology·D J Loskutoff, F Samad
May 13, 1998·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·B Janand-DelenneP Vague
May 14, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·P E MorangeI Juhan-Vague
Jun 9, 1999·Proceedings of the National Academy of Sciences of the United States of America·F SamadD J Loskutoff
Sep 16, 1999·The Journal of Clinical Endocrinology and Metabolism·D L CrandallJ G Kral
Feb 11, 2000·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·F Hube, H Hauner
Mar 7, 2000·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·J P BastardB Hainque
Apr 19, 2000·The Journal of Clinical Endocrinology and Metabolism·T K NordtB E Sobel
Jun 15, 2000·The New England Journal of Medicine·H P Kohler, P J Grant
Jul 6, 2000·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·V van HarmelenP Arner
Jul 21, 2000·The Journal of Clinical Endocrinology and Metabolism·D L CrandallJ G Kral

❮ Previous
Next ❯

Citations

Oct 5, 2013·Journal of Mammary Gland Biology and Neoplasia·Nikki A FordStephen D Hursting
Jan 25, 2011·Journal of Thrombosis and Thrombolysis·Yukinori TamuraOsamu Matsuo
Oct 4, 2005·Lancet·David W Haslam, W Philip T James
Mar 23, 2006·International Journal of Obesity : Journal of the International Association for the Study of Obesity·A SaikiK Shirai
Sep 9, 2008·European Heart Journal·Gideon R HajerFrank L J Visseren
Dec 13, 2005·The Journal of Clinical Investigation·Stuart P WeisbergAnthony W Ferrante
Jul 4, 2012·Journal of Neuroinflammation·Hyejin JeonKyoungho Suk
Dec 25, 2007·Nutrition & Metabolism·Aldi T KrajaIngrid B Borecki
Nov 28, 2013·Cancer & Metabolism·Stephen D HurstingLaura M Lashinger
Feb 16, 2006·Clinical Chemistry and Laboratory Medicine : CCLM·Chinhnam HathucAlejandro Gugliucci
May 26, 2012·Journal of the American Society of Nephrology : JASN·Frederic T BillingsNancy J Brown
Sep 6, 2008·International Journal of Medical Sciences·Hidekuni Inadera
Nov 8, 2013·Journal of Thrombosis and Thrombolysis·Mehmet AgirbasliDouglas E Vaughan
Nov 12, 2014·TheScientificWorldJournal·Songul Yasar YildizMehmet Agirbasli
Sep 21, 2012·Expert Review of Hematology·Claudio AnnaloroGiorgio Lambertenghi Deliliers
Apr 24, 2009·Clinical and Experimental Hypertension : CHE·Katsutaka Oishi
Dec 16, 2005·The American Journal of the Medical Sciences·Louise Hutley, Johannes B Prins
Jan 29, 2016·BMC Obesity·Madhusudhan C VarmaPhilip G McTernan
Jan 5, 2010·The Journal of Steroid Biochemistry and Molecular Biology·Claudia A Staab, Edmund Maser
Jan 27, 2009·Journal of Molecular and Cellular Cardiology·Katsutaka OishiNorio Ishida
Oct 31, 2007·Biochemical and Biophysical Research Communications·Jiyun AhnTaeyoul Ha
Oct 24, 2014·Thrombosis and Haemostasis·F MolicaS Steffens
Jul 20, 2005·Acta Physiologica Scandinavica·P Trayhurn

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.